SCHEMBL4894792

SCHEMBL4894792

CCCc1nc(NC(=O)C(CC)c2ccccc2)c(C(=O)OC(C)(C)C)n1CC(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
ELOVL1 Q9BW60 1/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CRHBP P24387 2/20 0.40
CRHR2 Q13324 2/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KCNQ2 O43526 4/20 0.39
KCNQ3 O43525 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
KCNE1 P15382 1/20 0.39
KCNQ1 P51787 1/20 0.39
KCNQ4 P56696 1/20 0.39
HDAC3 O15379 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4892115 0.90 ALDH1A1 (0.44) ALDH1A1ELOVL1POLBMEN1KMT2A
SCHEMBL3442115 0.74 ELOVL1 (0.47) ALDH1A1ELOVL1POLBMEN1KMT2A
SCHEMBL4667721 0.74 ELOVL1 (0.49) ALDH1A1ELOVL1POLBMEN1KMT2A
SCHEMBL4576752 0.65 POLB (0.43) ALDH1A1ELOVL1POLBMEN1KMT2A
SCHEMBL2293652 0.63 MEN1 (0.55) ALDH1A1POLBMEN1KMT2ALMNA
SCHEMBL4577091 0.63 ALDH1A1 (0.46) ALDH1A1ELOVL1POLBMEN1KMT2A
SCHEMBL4890027 0.63 ADORA3 (0.43) ALDH1A1CRHBPCRHR2LMNAHTT
SCHEMBL19074542 0.62 ALDH1A1 (0.82) ALDH1A1POLBMEN1KMT2ACRHBP
SCHEMBL7752354 0.62 ALDH1A1 (0.82) ALDH1A1POLBMEN1KMT2ACRHBP
SCHEMBL20788013 0.62 POLB (0.72) ALDH1A1POLBMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US claimed
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed
WO-2007073299-A1 IMIDAZOLES AS GABA-B RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators GABRB1, GABBR2, GABRB2 ALDH1A1 1448/4885ELOVL1 3455/4885POLB 3128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.